226 related articles for article (PubMed ID: 10371502)
1. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine.
Cafaro A; Caputo A; Fracasso C; Maggiorella MT; Goletti D; Baroncelli S; Pace M; Sernicola L; Koanga-Mogtomo ML; Betti M; Borsetti A; Belli R; Akerblom L; Corrias F; Buttò S; Heeney J; Verani P; Titti F; Ensoli B
Nat Med; 1999 Jun; 5(6):643-50. PubMed ID: 10371502
[TBL] [Abstract][Full Text] [Related]
2. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.
Maggiorella MT; Baroncelli S; Michelini Z; Fanales-Belasio E; Moretti S; Sernicola L; Cara A; Negri DR; Buttò S; Fiorelli V; Tripiciano A; Scoglio A; Caputo A; Borsetti A; Ridolfi B; Bona R; ten Haaft P; Macchia I; Leone P; Pavone-Cossut MR; Nappi F; Ciccozzi M; Heeney J; Titti F; Cafaro A; Ensoli B
Vaccine; 2004 Sep; 22(25-26):3258-69. PubMed ID: 15308348
[TBL] [Abstract][Full Text] [Related]
3. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
4. Control of viral replication and disease onset in cynomolgus monkeys by HIV-1 TAT vaccine.
Ensoli B; Cafaro A
J Biol Regul Homeost Agents; 2000; 14(1):22-6. PubMed ID: 10763887
[TBL] [Abstract][Full Text] [Related]
5. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
[TBL] [Abstract][Full Text] [Related]
6. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine.
Cafaro A; Caputo A; Maggiorella MT; Baroncelli S; Fracasso C; Pace M; Borsetti A; Sernicola L; Negri DR; Ten Haaft P; Betti M; Michelini Z; Macchia I; Fanales-Belasio E; Belli R; Corrias F; Buttò S; Verani P; Titti F; Ensoli B
J Med Primatol; 2000 Aug; 29(3-4):193-208. PubMed ID: 11085582
[TBL] [Abstract][Full Text] [Related]
7. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
8. Innate anti-viral immunity is associated with the protection elicited by the simian immunodeficiency virus (SIV) live attenuated virus vaccine in cynomolgus monkeys.
Goletti D; Macchia I; Leone P; Pace M; Sernicola L; Pavone-Cossut MR; Maggiorella MT; Cafaro A; Ensoli B; Titti F
Med Sci Monit; 2006 Oct; 12(10):BR330-40. PubMed ID: 17006396
[TBL] [Abstract][Full Text] [Related]
9. Protection of macaques against a SHIV with a homologous HIV-1 Env and a pathogenic SHIV-89.6P with a heterologous Env by vaccination with multiple gene-deleted SHIVs.
Ui M; Kuwata T; Igarashi T; Ibuki K; Miyazaki Y; Kozyrev IL; Enose Y; Shimada T; Uesaka H; Yamamoto H; Miura T; Hayami M
Virology; 1999 Dec; 265(2):252-63. PubMed ID: 10600597
[TBL] [Abstract][Full Text] [Related]
10. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
11. The impact of early immune destruction on the kinetics of postacute viral replication in rhesus monkey infected with the simian-human immunodeficiency virus 89.6P.
Zhang ZQ; Schleif WA; Casimiro DR; Handt L; Chen M; Davies ME; Liang X; Fu TM; Tang A; Wilson KA; McElhaugh M; Carella A; Tan C; Connolly B; Hill S; Klein H; Emini EA; Shiver JW
Virology; 2004 Mar; 320(1):75-84. PubMed ID: 15003864
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
13. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
[TBL] [Abstract][Full Text] [Related]
14. Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys.
Borsetti A; Baroncelli S; Maggiorella MT; Bellino S; Moretti S; Sernicola L; Belli R; Ridolfi B; Farcomeni S; Negri DR; Cafaro A; Ensoli B; Titti F
Arch Virol; 2008; 153(3):463-72. PubMed ID: 18080858
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
16. Induction of immune response in macaque monkeys infected with simian-human immunodeficiency virus having the TNF-alpha gene at an early stage of infection.
Shimizu Y; Miyazaki Y; Ibuki K; Suzuki H; Kaneyasu K; Goto Y; Hayami M; Miura T; Haga T
Virology; 2005 Dec; 343(2):151-61. PubMed ID: 16169034
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
[TBL] [Abstract][Full Text] [Related]
18. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
19. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
20. A genetically engineered live-attenuated simian-human immunodeficiency virus that co-expresses the RANTES gene improves the magnitude of cellular immunity in rhesus macaques.
Shimizu Y; Inaba K; Kaneyasu K; Ibuki K; Himeno A; Okoba M; Goto Y; Hayami M; Miura T; Haga T
Virology; 2007 Apr; 361(1):68-79. PubMed ID: 17157892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
